Are you ready to drop Jakafi from your options.
UK’s National Institute for Health Excellence (NICE) influences about 25% of the world’s prescription of novel drugs.
It is currently reviewing the cost-effectiveness of ruxolitinib (JAKAVI/JAKAFI) for myelofibrosis and soliciting input from the affected patient population.
We need individual patients to go to the NICE website and provide feedback before the 7th of March. This is a life and death issue for our fellow MPN patients and the new US severe budget cutbacks assure a harder look at coverage for Jakafi in the States as well.
Speak out now..there’s not much time to register your opinion.